{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Alafenamide+%28TAF%29", "query": { "intervention": "Tenofovir Alafenamide (TAF)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 142, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tenofovir+Alafenamide+%28TAF%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T14:47:00.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02071082", "title": "Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HBV" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2014-02-25", "completion_date": "2016-10-26", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071082" }, { "nct_id": "NCT02269917", "title": "Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Type 1" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "Boosted Protease Inhibitor (bPI)", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1149, "start_date": "2015-03", "completion_date": "2020-10", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 38, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269917" }, { "nct_id": "NCT06630286", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "PTM B/F/TAF", "type": "DRUG" }, { "name": "PTM ISL/LEN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 609, "start_date": "2024-10-09", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630286" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT01780506", "title": "Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 872, "start_date": "2012-12-26", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01780506" }, { "nct_id": "NCT02984852", "title": "Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Darunavir (DRV)", "type": "DRUG" }, { "name": "Cobicistat (COBI)", "type": "DRUG" }, { "name": "Emtricitabine (FTC)", "type": "DRUG" }, { "name": "Tenofovir Alafenamide (TAF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Scientific Affairs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2016-12", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02984852" }, { "nct_id": "NCT02556333", "title": "Emtricitabine/Tenofovir Alafenamide as Salvage ART", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "14 Years to 100 Years" }, "enrollment_count": 1, "start_date": "2015-09-16", "completion_date": "2016-08-16", "has_results": true, "last_update_posted_date": "2017-11-14", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556333" }, { "nct_id": "NCT03631732", "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "B/F/TAF", "type": "DRUG" }, { "name": "NRTIs", "type": "DRUG" }, { "name": "Third Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 496, "start_date": "2018-08-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631732" }, { "nct_id": "NCT06891066", "title": "A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus Type 1 (HIV-1) Infection" ], "interventions": [ { "name": "ISL", "type": "DRUG" }, { "name": "ULO", "type": "DRUG" }, { "name": "BIC/FTC/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-04-14", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 11, "location_summary": "San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06891066" }, { "nct_id": "NCT03656783", "title": "Effects of Biktarvy on CFR in Stable HIV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Biktarvy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 25, "start_date": "2018-09-14", "completion_date": "2021-09-15", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-01T14:47:00.658Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03656783" } ] }